Caleb Dunlap, MD
Family Medicine · Jacksonville, FLNPI 1104386473
Payments from drug & device makers
Across 266 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Bayer$613
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$383
- Amgen$369
- Astellas Pharma US Inc$293
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,102100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,348 |
| AstraZeneca | 37 | $1,305 |
| Bayer | 30 | $613 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $383 |
| Amgen | 16 | $369 |
| Astellas Pharma US Inc | 12 | $293 |
| Lilly USA, LLC | 16 | $279 |
| Otsuka America Pharmaceutical, Inc. | 11 | $245 |
| GSK | 13 | $239 |
| Boston Scientific | 2 | $232 |
| Abbott | 10 | $215 |
| Johnson & Johnson | 1 | $189 |
| Merck | 2 | $144 |
| Medtronic | 3 | $116 |
| Vertos Medical, Inc. | 1 | $105 |
| Bard Peripheral Vascular, Inc. | 1 | $100 |
| Novo Nordisk | 4 | $93 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Pfizer | 5 | $87 |
| Painteq LLC | 1 | $74 |
| Novartis | 4 | $69 |
| Exact Sciences | 4 | $69 |
| Sumitomo Pharma America, Inc. | 4 | $67 |
| Philips North America LLC | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Lundbeck LLC | 2 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Sanofi | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Abiomed | 1 | $23 |
| Breas Medical, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$567
- FARXIGA$448
- BREZTRI$336
- VRAYLAR$250
- Monarch Platform$189
- NEXPLANON$131
- CAPLYTA$130
- WATCHMAN Access System$125
- QULIPTA$123
- mild Device Kit$105
- Veozah$103
- VENOVO$100
How this compares
$7,109 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $143,108 |
| EliquisApixaban | 314 | $128,390 |
| VraylarCariprazine Hcl | 68 | $105,158 |
| MounjaroTirzepatide | 97 | $86,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $84,176 |
| JardianceEmpagliflozin | 36 | $43,439 |
| MyrbetriqMirabegron | 60 | $39,860 |
| FarxigaDapagliflozin Propanediol | 32 | $39,842 |
| EntrestoSacubitril/Valsartan | 93 | $37,119 |
| JanuviaSitagliptin Phosphate | 40 | $36,663 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $34,555 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $34,206 |
| LinzessLinaclotide | 37 | $33,932 |
| TrulicityDulaglutide | 20 | $20,441 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Restasis | $1,348 | $146,111123 claims |
| Novo NordiskOzempic | $93 | $143,108101 claims |
| PfizerEliquis, Abrysvo | $87 | $133,125328 claims |
| Lilly USA, LLCMounjaro, Trulicity | $279 | $107,006117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $239 | $94,198126 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,305 | $88,158132 claims |
| Astellas Pharma US IncMyrbetriq | $293 | $39,86060 claims |
| NovartisEntresto | $69 | $37,11993 claims |
| MerckJanuvia | $144 | $36,66340 claims |
| Sanofi-aventis U.S. LLCMultaq | $41 | $9,83722 claims |
| BayerKerendia | $613 | $8,30511 claims |
| Johnson & JohnsonXarelto | $189 | $7,69816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Jacksonville
- Jeffry JacqmeinJacksonville$8.7M
- Herman DowneyJacksonville$4.1M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.